Lineage Cell Therapeutics, Inc. (LCTX)

Healthcare · Biological Products, (No Diagnostic Substances) · Price $1.11
Updated: Aug 31, 2026
Net Income (TTM)
$-66.9M
Trailing 12 Months
Growth Rate
N/A
Log-Linear Regression (0Q)
Price/Earnings
N/A
Valuation Multiple
EPS (Diluted)
$-0.19
Net Income / Shares
Net Margin
-511.07%
Profitability

🧮 LCTX Net Income Breakdown

Net Income = Revenue - All Expenses - Taxes - Interest
Revenue (Top Line) $13.1M
Less: Cost of Revenue → Gross Profit $9.3M
Less: Operating Expenses → Operating Income $-26.9M
Less: Interest Expense N/A
Less: Income Tax Expense $0
Equals: Net Income (Bottom Line) $-66.9M

Understanding Net Income

Net income, also called the "bottom line" or net profit, is the money a company keeps after paying all expenses including cost of goods, operating costs, interest, and taxes. For LCTX, the trailing twelve month net income is $-66.9M.

Why Net Income Matters

Net income is the ultimate measure of accounting profitability. It determines earnings per share (EPS), affects stock valuations through the P/E ratio, and represents the theoretical amount available to shareholders. However, net income can be influenced by accounting choices, which is why value investors often look at cash flow metrics alongside it.

LCTX's net income growth rate of N/A (based on log-linear regression of 0 quarters) indicates relatively flat or slightly declining profitability.

Net Income vs Cash Flow Metrics

Free Cash Flow: $-22.6M →

Actual cash generated after capital expenditures. FCF often differs from net income due to depreciation, working capital changes, and capex timing.

Owner Earnings: $-22.4M →

Buffett's preferred metric that adds back depreciation but subtracts maintenance capex. Often considered more accurate than net income.

EPS (Diluted): $-0.19 →

Net income divided by diluted shares outstanding. The primary driver of the P/E ratio used in valuations.

Revenue: $13.1M →

The top line that net income is derived from. Net margin shows what percentage of revenue becomes profit.

P/E Ratio Analysis

LCTX's P/E ratio of N/A means investors pay $N/A for every $1 of annual earnings.

Net Margin: Profitability Efficiency

Net margin of -511.07% shows what percentage of LCTX's revenue converts to profit after all costs. Negative net margins indicate the company is losing money on operations.

Summary: LCTX Net Income Trend

Lineage Cell Therapeutics, Inc. (LCTX) has a negative net margin of -511.07% — the company is currently loss-making at the bottom line. Net income trend: N/A annually — a negative trend — revenue erosion that warrants monitoring. For complete financial analysis, view the full LCTX stock report on Zyberno.

Frequently Asked Questions

What is LCTX's current net income?

Lineage Cell Therapeutics, Inc.'s TTM net income is $-66.9M, growing at N/A annually — a negative trend — revenue erosion that warrants monitoring.

Is LCTX's net income growing?

Lineage Cell Therapeutics, Inc. (LCTX) has a negative net margin of -511.07% — the company is currently loss-making at the bottom line. Net income trend: N/A annually — a negative trend — revenue erosion that warrants monitoring.

What is LCTX's net profit margin?

Lineage Cell Therapeutics, Inc. (LCTX) has a negative net margin of -511.07% — the company is currently loss-making at the bottom line. Net income trend: N/A annually — a negative trend — revenue erosion that warrants monitoring.

What is LCTX's P/E ratio?

LCTX's P/E ratio is N/A, meaning the market values the company at N/A times its annual earnings.

How does net income differ from free cash flow?

Net income is an accounting measure that includes non-cash items like depreciation, while free cash flow shows actual cash generated. LCTX's net income is $-66.9M versus free cash flow of $-22.6M. Large differences often indicate significant capital expenditures or working capital changes.

📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
🛡️
Margin of Safety
Valuation Gap
🎯
Expected Return
Projected Annual
Click any metric for full methodology and detailed analysis

📊 Full LCTX Stock Report

See LCTX's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

💵 LCTX Free Cash Flow

Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.

💰 LCTX Owner Earnings

Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.

📈 LCTX Earnings Per Share

Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.

🎯 LCTX Earnings Surprise (SUE)

See whether LCTX is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

📊 LCTX Revenue

Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.

💰 LCTX Net Income

Analyze the bottom-line profit, P/E ratio, and net profit margin trends.

🔶 LCTX Operating Income

Analyze EBIT, operating margin, and core business profitability before interest and taxes.

💜 LCTX Gross Profit

Analyze gross margin, pricing power, and profitability before operating expenses.

View Full LCTX Report Find More Quality Stocks
Scroll to Top